Clinical Trial Update: Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

Safety issues reported for peribulbar injection of umbilical cord-derived mesenchymal stem cells in Retinitis Pigmentosa patients from a Phase 1/2 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• UC-MSC (umbilical cord-derived mesenchymal stem cells) (umbilical cord-derived mesenchymal stem cells)

Snippet

Sponsor: PT. Prodia Stem Cell Indonesia | Conditions: Retinitis Pigmentosa | Phase 1, Phase 2 | Status: COMPLETED